Just noticed analysts have cut their price target on Oncopeptides AB pretty significantly. The average target dropped to 2.86 kr, down nearly 46% from where they had it back in February. That's a pretty sharp revision for a biotech play. Current estimates are ranging from 2.83 to 2.94 kr, which would still represent decent upside from the latest closing price of 1.78 kr if those targets hold. Interesting part is the fund activity though. Only one institution is really holding a meaningful position, and they actually trimmed their stake over the last few months. SPDR Portfolio Europe ETF cut their shares by about 70%, going from 14K down to 8K. They also reduced their overall portfolio weight in the stock by over 4% last quarter. So you're seeing both analyst skepticism and institutional pullback at the same time. Worth watching how this develops.